PIONEER REAL Japan: Baseline characteristics of a multicenter, prospective, real-world study of oral semaglutide in adults with type 2 diabetes in clinical practice in Japan

IF 3.1 3区医学 Q2 ENDOCRINOLOGY & METABOLISM

Journal of Diabetes Investigation Pub Date : 2024-05-06 DOI:10.1111/jdi.14219

Ryo Suzuki, Hanan Amadid, Atheline Major-Pedersen, Daisuke Yabe

{"title":"PIONEER REAL Japan: Baseline characteristics of a multicenter, prospective, real-world study of oral semaglutide in adults with type 2 diabetes in clinical practice in Japan","authors":"Ryo Suzuki, Hanan Amadid, Atheline Major-Pedersen, Daisuke Yabe","doi":"10.1111/jdi.14219","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aims/Introduction</h3>\n \n <p>PIONEER REAL Japan was a non-interventional, multicenter, prospective study investigating oral semaglutide in adults with type 2 diabetes in routine clinical practice. We report baseline characteristics of participants enrolled in this study.</p>\n </section>\n \n <section>\n \n <h3> Materials and Methods</h3>\n \n <p>Adults aged ≥20 years with type 2 diabetes but no previous treatment with injectable glucose-lowering medication were enrolled. Participants initiated oral semaglutide at their treating physician's discretion and were followed for 34–44 weeks. Participants were stratified into <75-year-old and ≥75-year-old subgroups.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A total of 624 participants initiated the study. The mean (standard deviation) age was 64.1 years (14.1), the mean (standard deviation) body weight was 72.4 kg (16.1), and the mean (standard deviation) body mass index was 27.5 kg/m<sup>2</sup> (5.0). Participants had a median (interquartile range) type 2 diabetes duration of 9.3 years (4.2, 15.2) and mean (standard deviation) glycated hemoglobin 7.7% (1.1). Most (75.6%) participants were taking glucose-lowering medications at baseline; the most common was metformin (51.9%). The main reasons for initiating oral semaglutide were glycemic control and weight loss. Most (86.0%) participants had an individualized target for glycemic control of glycated hemoglobin ≤7%. The <75-year-old subgroup was heavier (mean [standard deviation] body mass index 28.6 kg/m<sup>2</sup> [5.2] vs 25.1 kg/m<sup>2</sup> [3.4]) but had comparable glycated hemoglobin levels (mean [standard deviation] 7.7% [1.2] vs 7.8% [1.0]) to the ≥75-year-old subgroup.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>PIONEER REAL Japan describes the characteristics of individuals with type 2 diabetes prescribed oral semaglutide. The baseline characteristics provide insights into Japanese individuals with type 2 diabetes prescribed oral semaglutide in clinical practice.</p>\n </section>\n </div>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":null,"pages":null},"PeriodicalIF":3.1000,"publicationDate":"2024-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11292382/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Diabetes Investigation","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jdi.14219","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Aims/Introduction

PIONEER REAL Japan was a non-interventional, multicenter, prospective study investigating oral semaglutide in adults with type 2 diabetes in routine clinical practice. We report baseline characteristics of participants enrolled in this study.

Materials and Methods

Adults aged ≥20 years with type 2 diabetes but no previous treatment with injectable glucose-lowering medication were enrolled. Participants initiated oral semaglutide at their treating physician's discretion and were followed for 34–44 weeks. Participants were stratified into <75-year-old and ≥75-year-old subgroups.

Results

A total of 624 participants initiated the study. The mean (standard deviation) age was 64.1 years (14.1), the mean (standard deviation) body weight was 72.4 kg (16.1), and the mean (standard deviation) body mass index was 27.5 kg/m² (5.0). Participants had a median (interquartile range) type 2 diabetes duration of 9.3 years (4.2, 15.2) and mean (standard deviation) glycated hemoglobin 7.7% (1.1). Most (75.6%) participants were taking glucose-lowering medications at baseline; the most common was metformin (51.9%). The main reasons for initiating oral semaglutide were glycemic control and weight loss. Most (86.0%) participants had an individualized target for glycemic control of glycated hemoglobin ≤7%. The <75-year-old subgroup was heavier (mean [standard deviation] body mass index 28.6 kg/m² [5.2] vs 25.1 kg/m² [3.4]) but had comparable glycated hemoglobin levels (mean [standard deviation] 7.7% [1.2] vs 7.8% [1.0]) to the ≥75-year-old subgroup.

Conclusions

PIONEER REAL Japan describes the characteristics of individuals with type 2 diabetes prescribed oral semaglutide. The baseline characteristics provide insights into Japanese individuals with type 2 diabetes prescribed oral semaglutide in clinical practice.

Abstract Image

查看原文本刊更多论文

日本 PIONEER REAL：一项针对日本临床实践中 2 型糖尿病成人患者口服塞马鲁肽的多中心、前瞻性、真实世界研究的基线特征。

目的/简介：日本 PIONEER REAL 是一项非干预性、多中心、前瞻性研究，旨在调查常规临床实践中成人 2 型糖尿病患者口服塞马鲁肽的情况。我们报告了这项研究参与者的基线特征：研究对象为年龄≥20 岁、患有 2 型糖尿病但之前未接受过注射降糖药物治疗的成人。参与者根据主治医生的决定开始口服塞马鲁肽，并接受 34-44 周的随访。研究结果共有 624 名参与者开始了研究。平均（标准差）年龄为 64.1 岁（14.1），平均（标准差）体重为 72.4 公斤（16.1），平均（标准差）体重指数为 27.5 公斤/平方米（5.0）。参与者的 2 型糖尿病病程中位数（四分位数间距）为 9.3 年（4.2，15.2），糖化血红蛋白平均值（标准差）为 7.7% (1.1)。大多数参与者（75.6%）在基线时正在服用降糖药物，其中最常见的是二甲双胍（51.9%）。开始口服塞马鲁肽的主要原因是控制血糖和减轻体重。大多数参与者（86.0%）的个体化血糖控制目标是糖化血红蛋白≤7%。但糖化血红蛋白水平（平均值 [标准差] 7.7% [1.2] vs 7.8% [1.0]）与≥75 岁亚组相当：PIONEER REAL Japan描述了口服塞马鲁肽的2型糖尿病患者的特征。结论：PIONEER REAL Japan描述了口服塞马鲁肽的2型糖尿病患者的特征，其基线特征有助于了解日本2型糖尿病患者在临床实践中口服塞马鲁肽的情况。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Diabetes Investigation ENDOCRINOLOGY & METABOLISM-

CiteScore

6.50

自引率

9.40%

发文量

218

审稿时长

6-12 weeks

期刊介绍： Journal of Diabetes Investigation is your core diabetes journal from Asia; the official journal of the Asian Association for the Study of Diabetes (AASD). The journal publishes original research, country reports, commentaries, reviews, mini-reviews, case reports, letters, as well as editorials and news. Embracing clinical and experimental research in diabetes and related areas, the Journal of Diabetes Investigation includes aspects of prevention, treatment, as well as molecular aspects and pathophysiology. Translational research focused on the exchange of ideas between clinicians and researchers is also welcome. Journal of Diabetes Investigation is indexed by Science Citation Index Expanded (SCIE).